Yuanhe Pharmaceutical Group Lndustry Co., Ltd.

Primary Objective: To investigate the relative bioavailability of the test formulation, irbesartan/hydrochlorothiazide tablets (150 mg/12.5 mg: each tablet contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide, manufactured by Yuanhe Pharmaceutical Co., Ltd.), and the reference formulation, irbesartan/hydrochlorothiazide tablets (trade name: Ambono®; COAPROVEL®, 150 mg/12.5 mg: each tablet contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide, manufactured by Sanofi Winthrop Industrie), in healthy Chinese subjects after a single oral administration on both fasting and after a meal. Pharmacokinetic parameters of the two formulations were analyzed, and their bioequivalence was evaluated. Secondary Objective: To evaluate the safety of irbesartan/hydrochlorothiazide tablets after a single oral administration on both fasting and after a meal in healthy adult Chinese subjects.

The pharmacokinetics of the test preparation irbesartan hydrochlorothiazide capsules (Anlibo, specifications: 150 mg/12.5 mg/capsule, produced by Yuanhe Pharmaceutical Co., Ltd.) and the reference preparation irbesartan hydrochlorothiazide tablets (Anbono®, specifications: 150 mg/12.5 mg/tablet; produced by Sanofi Clir SNC) were studied in healthy subjects after a single oral administration under fasting and fed conditions, and the bioequivalence of the two preparations in fasting and fed conditions, as well as their safety in healthy subjects were evaluated.

Primary objective: To verify that Verapamil Hydrochloride Delayed-Release Tablets are superior to placebo in reducing morning diastolic blood pressure (ambulatory blood pressure) after 8 weeks of treatment: To evaluate the safety of Verapamil Hydrochloride Delayed-Release Tablets in hypertensive subjects after 8 weeks of treatment. Secondary objectives: Verapamil Hydrochloride Delayed-Release Tablets are superior to placebo in reducing office blood pressure after 4 and 8 weeks of treatment; The proportion of subjects who need to increase the amount of Verapamil Hydrochloride Delayed-Release Tablets after 4 weeks of treatment.